| Literature DB >> 29368067 |
Marek Rychter1,2, Anna Baranowska-Korczyc3, Bartłomiej Milanowski4, Marcin Jarek3, Barbara M Maciejewska3,5, Emerson L Coy3, Janina Lulek4.
Abstract
PURPOSE: TEntities:
Keywords: cilostazol; drug delivery system; electrospinning; polycaprolactone; tissue regeneration
Mesh:
Substances:
Year: 2018 PMID: 29368067 PMCID: PMC5784006 DOI: 10.1007/s11095-017-2314-0
Source DB: PubMed Journal: Pharm Res ISSN: 0724-8741 Impact factor: 4.200
Fig. 1Scheme of an electrospinning setup for the fabrication of PCL fibers.
Fig. 2Calculated electrospinning efficiencies for PCL fibrous mats (a) and CIL loaded PCL fibrous mats (b) obtained by weighting substrates and products. Estimated CIL entrapment efficiencies (c) for various CIL loaded fibers formulations based on CIL absorbance value (at 257 nm) after dissolving electrospun tubular structures.
A Comparison of the Average Diameters and Alignment Coherencies of Fibers from Inner and Outer Layer of Electrospun PCL Tubular Structures Collected on a Rotating Collector and a Stationary Collector
| Polymer solution in chloroform: methanol | Rotation speed (rpm) | Average diameter (μm) ± SD | Average coherency ± SD | ||
|---|---|---|---|---|---|
| inner | outer | inner | outer | ||
| 8% PCL | 0 | 0.81 ± 0.42 | – | – | |
| 1000 | 1.17 ± 0.47 | 1.18 ± 0.51 | 0.23 ± 0.11 | 0.35 ± 0.13 | |
| 2000 | 2.48 ± 0.95 | 2.33 ± 0.93 | 0.28 ± 0.13 | 0.56 ± 0.13 | |
| 4000 | 2.12 ± 0.68 | 2.48 ± 0.68 | 0.28 ± 0.12 | 0.61 ± 0.14 | |
| 8% PCL +6.25% CIL | 0 | 1.17 ± 0.20 | – | – | |
| 1000 | 1.38 ± 0.41 | 2.15 ± 0.57 | 0.33 ± 0.15 | 0.37 ± 0.17 | |
| 2000 | 1.38 ± 0.42 | 1.34 ± 0.34 | 0.25 ± 0.14 | 0.37 ± 0.17 | |
| 4000 | 0.77 ± 0.36 | 1.55 ± 0.53 | 0.21 ± 0.13 | 0.21 ± 0.11 | |
| 8% PCL +12.50% CIL | 0 | 1.67 ± 0.30 | – | – | |
| 1000 | 0.96 ± 0.53 | 1.24 ± 0.52 | 0.28 ± 0.12 | 0.27 ± 0.13 | |
| 2000 | 1.08 ± 0.38 | 1.76 ± 0.48 | 0.22 ± 0.10 | 0.23 ± 0.14 | |
| 4000 | 1.50 ± 0.78 | 1.43 ± 0.47 | 0.20 ± 0.11 | 0.24 ± 0.11 | |
| 8% PCL +18.75% CIL | 0 | 1.56 ± 0.41 | – | – | |
| 1000 | 1.68 ± 0.65 | 1.55 ± 0.43 | 0.15 ± 0.07 | 0.29 ± 0.10 | |
| 2000 | 1.15 ± 0.32 | 1.52 ± 0.43 | 0.16 ± 0.08 | 0.17 ± 0.08 | |
| 4000 | 1.51 ± 0.47 | 1.79 ± 0.51 | 0.15 ± 0.07 | 0.20 ± 0.10 | |
Fig. 3Fiber orientation presented as a color-coded SEM micrographs of various formulations of PCL fibers. Fiber orientation angle corresponds to a color from the bar presented at the bottom. Histograms demonstrating fiber orientation distribution are presented below each color-coded SEM micrograph. L and C refer to the longitudinal and circumferential directions of the electrospun sample.
Fig. 4SEM micrographs of 8% (wt) PCL fibrous mats: without CIL (a), loaded with 6.25% CIL (b), loaded with 12.50% CIL (c), loaded with 18.75% CIL (d).
Fig. 5DSC curves of CIL powder (a), PCL pellets (b), PCL fibrous mats (c) and PCL fibrous mats with 6.25% (d); 12.50% (e); 18.75% (f) of CIL. Inset represents stacked thermographs of various fiber formulations, visualizing shifts in the melting temperature of PCL.
Fig. 6FTIR spectra of CIL powder (a), as prepared PCL fibrous mats (b) and PCL fibrous mats with 6.25% (c); 12.50% (d); 18.75% (e) of CIL. The left inset represents stacked spectra of various fiber formulations: the intensity of the peaks increases with increasing CIL content. The right inset demonstrates lower peaks intensity, which is characteristic for PCL with the presence of CIL.
Fig. 7Raman spectra of CIL (a), PCL fibrous mats (b) and PCL fibrous mats with 6.25% (c); 12.50% (d); 18.75% (e) of CIL. The inset represents two characteristic peaks for form A of CIL which intensity increased with an increase in drug content.
Fig. 8XRD patterns of the prepared PCL fibrous mats (a) and CIL powder (b) as well as PCL fibrous mats with 6.25% (c), 12.50% (d), 18.75% (e) of CIL. The inset represents stacked spectra of various fiber formulations and demonstrates the influence of CIL presence on the crystallinity of PCL.
Fig. 9Mean fiber diameter, Young’s modulus and hardness of - PCL electrospun fibers as a function of PCL concentration (a), − PCL electrospun fibers with 6.25% of CIL as a function of PCL concentration (b), − 8% PCL electrospun fibers with CIL as a function of CIL concentration (c).
Fig. 10CIL release profiles from electrospun PCL materials loaded with 6.25%, 12.50% and 18.75% CIL (n = 4) in PBS (pH = 7.4) with temperature set at 37°C.
Fig. 11SEM micrographs before (a,b,c) and after (d, e, f) release studies of PCL materials loaded with 6.25% (a, d), 12.50% (b, e) and 18.75% (c, f) CIL.
Parameters Obtained by Fitting Four Different Models to the in vitro Release Data for Drug Release Kinetics Determination
| Formulation | Higuchi | Hixson-Crowell | Ritger-Peppas | Peppas-Sahlin | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| PCL + 6.25% CIL | 0.812 | 2.236 | 0.150 | 0.942 | 0.000 | 0.000 | 0.996 | 0.602 | 0.073 | 1.582 | 0.743 | 0.991 | 2.070 | 0.560 | 0.030 | 0.020 |
| PCL + 12.50% CIL | 0.940 | 1.535 | 0.229 | 0.975 | 0.000 | 0.000 | 0.991 | 0.875 | 0.056 | 0.130 | 0.068 | 0.989 | 0.304 | 0.216 | 0.045 | 0.007 |
| PCL + 18.75% CIL | 0.973 | 1.641 | 0.125 | 0.972 | 0.000 | 0.000 | 0.986 | 0.695 | 0.056 | 0.430 | 0.153 | 0.983 | 0.875 | 0.139 | 0.022 | 0.007 |